Merck's $8 Billion Cancer Vaccine Faces Pivotal First US Jury Trial

In a landmark development for the biotechnology industry, Merck & Co.'s groundbreaking cancer vaccine is set to undergo its first jury trial in the United States. This legal battle comes at a critical time as Merck seeks to reinforce its position in the competitive pharmaceutical market, highlighting the substantial financial stakes involved—amounting to a staggering $8 billion.

Continue reading